The antiparkinsonian activity of dopamine agonists and their interaction with central dopamine receptor subtypes.
Goldstein
M
M
Neurochemistry Research Laboratories, New York University Medical Center, New York 10016.
Lieberman
A N
AN
Takasugi
N
N
Shimizu
Y
Y
Kuga
S
S
D000818:Animals; D000978:Antiparkinson Agents / Q000008:administration & dosage*; D001921:Brain / Q000187:drug effects*; D004292:Dominance, Cerebral / Q000187:drug effects; D004298:Dopamine / Q000378:metabolism*; D015259:Dopamine Agents / Q000008:administration & dosage*; D000882:Haplorhini; D006801:Humans; D009434:Neural Pathways / Q000187:drug effects; D010300:Parkinson Disease / Q000188:drug therapy*; D011954:Receptors, Dopamine / Q000187:drug effects*
D000978:Antiparkinson Agents; D015259:Dopamine Agents; D011954:Receptors, Dopamine; D004298:Dopamine